The role of parametric feature maps to correct different volume of interest sizes: an in vivo liver MRI study
European Radiology Experimental volume 7, Article number: 48 (2023)
Different volume of interest (VOI) sizes influence radiomic features. This study examined if translating images into feature maps before feature sampling could compensate for these effects in liver magnetic resonance imaging (MRI).
T1- and T2-weighted sequences from three different scanners (two 3-T scanners, one 1.5-T scanner) of 66 patients with normal abdominal MRI were included retrospectively. Three differently sized VOIs (10, 20, and 30 mm in diameter) were drawn in the liver parenchyma (right lobe), excluding adjacent structures. Ninety-three features were extracted conventionally using PyRadiomics. All images were also converted to 93 parametric feature maps using a pretested software. Agreement between the three VOI sizes was assessed with overall concordance correlation coefficients (OCCCs), while OCCCs > 0.85 were rated reproducible. OCCCs were calculated twice: for the VOI sizes of 10, 20, and 30 mm and for those of 20 and 30 mm.
When extracted from original images, only 4 out of the 93 features were reproducible across all VOI sizes in T1- and T2-weighted images. When the smallest VOI was excluded, 5 features (T1-weighted) and 7 features (T2-weighted) were reproducible. Extraction from parametric maps increased the number of reproducible features to 9 (T1- and T2-weighted) across all VOIs. Excluding the 10-mm VOI, reproducibility improved to 16 (T1-weighted) and 55 features (T2-weighted). The stability of all other features also increased in feature maps.
Translating images into parametric maps before feature extraction improves reproducibility across different VOI sizes in normal liver MRI.
The size of the segmented VOI influences the feature quantity of radiomics, while software-based conversion of images into parametric feature maps before feature sampling improves reproducibility across different VOI sizes in MRI of normal liver tissue.
• Parametric feature maps can compensate for different VOI sizes.
• The effect seems dependent on the VOI sizes and the MRI sequence.
• Feature maps can visualize features throughout the entire image stack.
To gain high-dimensional data invisible to the human eye from radiological images with the “radiomics” approach and use these as quantitative imaging biomarkers appears promising [1, 2]. In this process, multiple quantitative features, based on texture, intensity, shape, and size, are extracted from digital images aiming to develop decision-supporting tools in medicine . For example, a recent study found a correlation between textural features of mice livers with intrahepatic tumor growth after injecting colon cancer cells before the metastases became visible to the human eye . Another group could predict malignancy in fat-suppressed T1-weighted magnetic resonance imaging (MRI) sequences of soft tissue tumors . A growing body of other studies showed correlations between feature behavior and different diagnostic endpoints such as tumor biology, tumor response, or therapy response [3, 5,6,7].
A translational gap exists between evolving scientific results and the still lacking application of radiomics in clinical practice . Poor reproducibility is the primary limitation of introducing radiomics into the clinical routine [8,9,10]. Both the intrinsic properties of the images, like different acquisition parameters, reconstruction algorithms, image noise, and resolution, and the postprocessing steps, like segmentation and applied software, affect feature reproducibility [11,12,13,14]. In particular, also the size of the segmented volume of interest (VOI) influences feature quantity [15,16,17,18,19]. Phantom and in vivo studies corroborated that differences in VOI size could cause significantly different results for many features, conceivably falsifying links between radiomics and biological endpoints [15, 16].
A recent phantom study proposed preprocessing radiological images into parametric feature maps to reduce the confounding effects of different VOI sizes . Parametric feature maps can be created with a pretested software tool that computes the whole image stack into a feature map stack. Separate feature maps are calculated for every feature analyzed. More precisely, the software divides the image into voxels of a defined voxel size so that all features are calculated for small, equally sized VOIs (i.e., the voxels). The resulting feature quantities are stored in the maps, where the gray levels reflect the quantity of the feature, e.g., regions in the maps with high quantities for the respective feature appear bright. Feature values can then be directly retrieved from the map in the same manner as Hounsfield units in a standard image viewer .
The aim of this study was to evaluate if parametric maps can correct for different VOI sizes in MRI of nonpathological livers.
The patient group was already included in a previous study with the approval of the institutional review board [EA1/104/19] . The study group comprised 66 patients examined in clinical routine between April 2012 and August 2020 to exclude a chronic inflammatory bowel disease. Examinations from three different MRI scanners were included. Only patients without disease were considered (i.e., the patient's record had to be devoid of disorders). Also, patients with liver lesions or parenchymal abnormalities (e.g., signal alteration between in-phase and opposed phase) and patients with metal implants (e.g., dorsal instrumentation or hip replacement) were excluded to avoid disturbing factors. Details of the patient population are summarized in Table 1.
MRI scanners and examination
Examinations were retrospectively screened from three different scanners: two 3-T scanners of the same model (Magnetom Skyra, Siemens Healthineers, Erlangen, Germany) and one 1.5-T scanner (Magnetom Aera, Siemens Healthineers, Erlangen, Germany). All scanners were calibrated regularly. The patients fasted for 4 h before the examination and were examined for 40 min with MRI enterography protocol after fractionally drinking 0.75 L of 2.5% mannitol solution within 1 h. Transverse T2-weighted turbo spin-echo (Half Fourier acquisition single-shot turbo spin-echo − HASTE) and the transverse T1-weighted gradient-echo (fast low angle shot − FLASH) sequences were analyzed in this study. Both sequences were acquired within the first 10 min of scanning before administering intravenous contrast in a fixed examination protocol. The field of view was adjusted to the individual patient’s size. Technical details of the MRI scanning parameters are listed in Table 2.
Sphere-shaped VOIs were drawn using 3D Slicer (Version 4.10.0, http://www.slicer.org) . VOIs were placed in liver segments 5, 6, 7, or 8 by a radiologist with over 4 years of experience in MRI (L.J.J.), aiming to exclude large blood vessels. We chose the right lobe of the liver due to less motion artifacts from cardiac pulsations . VOI diameters were set to 10, 20, and 30 mm since these are sizes to be expected for focal lesions such as metastases. Figure 1 shows an example of VOI placement in the original images.
Computing parametric feature maps
Parametric feature maps were computed using the pretested software tool of Kim et al. . This tool can create parametric maps for any feature available in PyRadiomics . Maps for 93 features were created per patient. Outsourced computing capacity accessible within the facility was used to shorten computation time. The voxel size and, therefore, the resolution of the maps was set to 5 mm for the computation since all chosen VOI diameters are multiples of this. With the x, y, and z-dimensions, the height and width of the voxels (which represent a grid of small VOIs) in the parametric maps can be defined, thus allowing the map's resolution to be adjusted. The z-resolution was adapted to match the slice thickness (5 mm). The x- and y-dimensions were set to 5 mm aiming for an adequate resolution of the images. The script containing the settings can be found in the Supplementary material (textfile S1). Figure 2 shows exemplary slices of different feature maps.
Feature extraction from the original images and from the feature maps
All feature classes available in PyRadiomics (Version 3.0.1) except “shape features” were included . Settings for the feature extraction were adjusted as recommended by the developers of PyRadiomics (see Supplementary material S2), and following the instructions of the Image Biomarker Standardization Initiative (see Supplementary material S3) . Ninety-three features were extracted: 18 first-order features (energy, total energy, entropy, kurtosis, maximum, minimum, mean, median, interquartile range, skewness, range, mean absolute deviation, robust mean absolute deviation, root mean squared, variance, uniformity, 10th percentile, and 90th percentile) and 75 second- and higher-order features (24 gray level co-occurrence matrix − GLCM features, 14 gray level dependence matrix − GLDM features, 16 gray level run-length matrix − GLRLM features, 16 gray level size zone matrix − GLSZM features, and five neighboring gray tone difference matrix − NGTDM features) . Shape features were not considered since VOI size was altered deliberately.
For extraction from the parametric maps, the VOIs were copied from the original images into the maps of each patient. The mean of each VOI was directly retrieved and described the feature quantity of the respective map. Figure 3 shows the VOI placement in exemplary feature maps.
Statistical analysis was performed using R (version 4.2.1, R Foundation for Statistical Computing) . A p value < 0.05 was considered to indicate statistical significance. To assess the multivariable agreement, overall concordance correlation coefficients (OCCCs), according to Lin et al.  and Barnhart et al. , were calculated with the epiR package . Like Rinaldi et al. , we considered features with an OCCC ≥ 0.85 stable and an OCCC < 0.85 nonreproducible. Reproducibility testing was applied to the results of the conventional feature extraction and the results of the parametric maps. Results were considered separately for each scanner.
Conventional feature extraction from the original images
Across the VOI sizes 10, 20, and 30 mm, features with an OCCC ≥ 0.85 were limited to first-order features but without consistency across scanners. Only the features mean, median, root mean squared, and 10th percentile were stable across scanners and T1-weighted and T2-weighted sequences. Supplementary material S4 contains OCCC data of the conventional extraction for all features, sequences, and scanners. To provide the reader with an overview of grayscale behavior in the images, simple statistics for each case (minimum, maximum, range) are provided in Supplementary material 5.
Feature reproducibility increased when OCCCs were calculated without the smallest VOI of 10 mm diameter. In T1-weighted and T2-weighted sequences, also 90th percentile was stable across scanners. In T2-weighted images, three GLDM-features (glcm_Id, glcm_InverseVariance, glcm_Idm) also showed OCCCs ≥ 0.85. For both the 3-T scanners, 13 other features were reproducible in T1-weighted images but not in T2-weighted images. Also, on each scanner, other features were reproducible. Supplementary material S6 summarizes data for the OCCCs calculated without the 10 mm diameter VOIs. The results of the conventional extraction were already reported in a previous study .
Feature extraction from the parametric maps
By directly extracting the feature quantities from the maps, OCCCs across the VOI sizes 10, 20, and 30 mm were above or equal to 0.85 for the same nine first-order features in T1-weighted and T2-weighted images. For both 3-T scanners, two second-/higher-order features (glrlm_RunLengthNonUniformity, glcm_JointEntropy) were reproducible in T1-weighted images. In addition, feature reproducibility increased overall, as shown in bar plots of the OCCCs in Supplementary material S7 separated per scanner for all VOI sizes. Supplementary material S8 contains numerical values of the OCCCs across the VOI sizes 10, 20, and 30 mm, and S9 across 20 and 30 mm. Although grayscale statistics can no longer be extracted from the maps, we also provide simple statistics for each case in supplementary material S10, where the minimum and maximum values were extracted from the corresponding map.
By excluding the smallest VOI from the OCCCs, stability improved in both T1-weighted and T2-weighted images. Nine first-order features were still reproducible in T1-weighted and 10 in T2-weighted images across all scanners. Seven additional second-/higher-order features became stable in T1-weighted, and 45 features in T2-weighted images. Agreement across the two 3-T scanners further increased with 39 additional reproducible features in T1-weighted and two additional features in T2-weighted images. OCCCs for the VOI sizes 20 and 30 mm separated per scanner are shown in Supplementary S11. Supplementary file S12 overviews the reproducible features for conventional and map extraction for the different scanners and sequences. Exemplary bar plots for OCCCs of 20 and 30 mm VOI sizes separated per scanner are shown in Fig. 4. In Fig. 5 boxplots of the conventional extraction and the map extraction of two examples across all three VOI sizes are compared.
Reproducibility across scanners and scanning parameters
Overall, the consistency of reproducible features between the two 3-T scanners was higher than the 1.5-T scanner in the conventional and map extraction (as shown in Supplementary file S12). As shown in Table 2, scanning parameters like matrix, phase encoding steps, repetition time (TR), and flip angle differed on all three scanners. When comparing the T2-weighted images on the two 3-T scanners, TR and flip angle were higher on scanner 2. Of note, more T2-weighted features were reproducible in the map extraction on scanner 2 (see Supplementary file S12).
This study showed that the agreement of feature quantity across the VOI sizes improved when features were extracted from the parametric feature maps. When all VOI sizes were included, 4 out of the 93 features were reproducible in the conventional extraction and 9 in the map extraction across all sequences and scanners. When the smallest VOI size of 10 mm was excluded, reproducibility across the 20 and 30 mm VOIs showed a maximum of 18 features when extracted conventionally and a maximum of 57 features when sampled from the maps, with differences between T1-weighted or T2-weighted and field strength. Therefore, when the smallest VOI size was excluded, reproducibility increased in both the conventional extraction from the original images and particularly in the maps. Of note, agreement of features with OCCCs < 0.85 still improved in the map extraction (as shown in Fig. 4). Greater consistency of reproducible features existed across the two 3-T scanners, in contrast to the 1.5-T scanner. Even though feature reproducibility improved on all scanners, the individual feature behavior did not resemble across different scanning parameters.
In other words, converting MRI liver images to parametric feature maps before feature extraction increases the reproducibility of radiomics across different VOI sizes of nonpathological liver tissue. Many features gained stability (OCCCs ≥ 0.85), while others notably improved. Results were even better when the smallest VOI size (10 mm diameter) was excluded, possibly indicating that the maps perform better with increasing VOI size. The findings of our study make an essential contribution to the reproducibility and application of radiomics in clinical routine.
Other groups already discussed different volumes of interest as a possible constraint for reproducibility. Santinha et al.  proposed a volume threshold for radiomics in their MRI phantom study. They reported a loss of informative content when features were extracted from small VOIs, while their volumes ranged from 0.8 to 29.8 cm3. Further studies presented efforts to mitigate volume-confounding effects. Saltybaeva et al.  performed predictive modeling in a multicenter MRI study on glioblastoma multiforme. They used intra-class correlation coefficients to eliminate features correlating with tumor volume from their analysis. Fave et al.  detected volume-dependent features with Spearman correlation coefficients in their study on non-small cell lung cancer tumors with volumes ranging from 5 to 567 cm3. Aiming to correct the five features with strong volume correlation in their study, they divided the values by the total number of voxels in the region of interest. Roy et al.  investigated the correlation between tumor volume and features in breast cancer lesions on MRI. In their approach, features with linear correlations were divided by the tumor volume, and inversely proportional features were multiplied. Features with nonlinear correlations were processed with principal component analysis, but some features were still volume-dependent even after dimension reduction. Shafiq-ul-Hassan et al. [33, 34] improved the reproducibility of radiomics by normalization of voxel size. Two other groups resampled the VOIs to isometric voxels before the feature extraction [35, 36]. In other studies, features prone to different volumes were excluded stepwise from the applied feature set [13, 37, 38]. In the present study, the calculation of parametric maps before feature extraction renders mathematical corrections of volume dependencies unnecessary. As a side effect, parametric maps also allow visualization of feature behavior.
Improving volume independence for liver-derived features could have been valuable to other study designs. For example, Zhang et al.  attempted to predict therapy response in patients with colorectal liver metastases. They delineated free-hand regions of interest around the largest cross-sectional area of the liver lesions in T2-weighted images acquired on a 3-T scanner. Lesions with a diameter greater than 1 cm were selected. They extracted five features (mean, variance, skewness, kurtosis, and entropy). Calculating parametric feature maps might have been beneficial in their study since variance, skewness, kurtosis, and entropy showed increased reproducibility across VOI sizes when extracted from the feature maps (yet, mean is also reproducible when derived conventionally from the original images). Another group  analyzed links between textural features and microvascular invasion in hepatocellular carcinoma in post-contrast-enhanced T1-weighted images. Resected specimens served as the reference standard. Features were also extracted based on the largest cross-sectional area of each lesion. Increasing the feature reproducibility by preprocessing images to parametric maps might also have been helpful, despite the influence of contrast media on the maps would still remain unclear.
Although by the map extraction, feature reproducibility improved throughout all three included scanners (two 3-T scanners and one 1.5-T scanner) scanner-wise, it is worth mentioning that the behavior of the individual features did not resemble across field strengths and scanning parameters. Different scanning parameters were applied on each scanner (e.g., phase encoding steps, matrix, TR, and flip angle), as shown in Table 2. Of note, in the map extraction, most features were reproducible on scanner #2 (one of the 3-T scanners, as indicated in Table 2), holding the highest flip angle and TR on T2-weighted sequences, conceivably indicating an enhancement of feature reproducibility through a better signal-to-noise ratio . The influence of different scanners and vendors, field strength, and scanning parameters are known obstacles concerning the reproducibility of MRI-derived radiomics and cannot be bypassed by the parametric feature maps [17, 42,43,44].
Our study has some limitations. Verification of the results in a larger patient cohort would have been desirable. Since enrollment was conducted strictly and only patients without liver lesions and abnormal signal alterations to the liver parenchyma were included, only 66 patients were eligible for a long retrospective screening period. Repeating the analysis in other organs would also have been interesting, but the spacious variation of the VOI would have been challenging in smaller organs like the spleen or pancreas. The limitation of the parametric feature maps is the required computing power. Calculating one feature map stack requires several hours of computing time. The computation process might have been accelerated if the original image stack had been cropped, which could possess a future applicability mode. Strictly limiting the map to the VOI, however, would lead to errors along the edges. But cropping the original image to a few voxels close to the VOI and then extracting the mean from the VOI in the map would reduce the required computing power and enhance effectiveness. Therefore, implementing a cropping step seems inevitable in further applications. It might be seen as a drawback that VOIs were drawn manually in our study. Since we aimed for control and transparency of the results, we preferred manual segmentation.
Software-based conversion of images into parametric feature maps before feature extraction improves feature reproducibility across different VOI sizes in normal liver tissue. Since the graphical presentation of the features in the maps provides insights into their behavior, disturbing factors such as artifacts may be elucidated. The general applicability of parametric maps to radiological images could also enable correction for differently sized VOIs in further studies on radiomics. Testing the applicability of the feature maps on focal liver lesions would be a future perspective.
Availability of data and materials
The datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request.
Magnetic resonance imaging
Overall concordance correlation coefficient
Volume of interest
Ng F, Ganeshan B, Kozarski R, Miles KA, Goh V (2013) Assessment of primary colorectal cancer heterogeneity by using whole-tumor texture analysis: contrast-enhanced CT texture as a biomarker of 5-year survival. Radiology 266:177–184. https://doi.org/10.1148/radiol.12120254
Gillies RJ, Kinahan PE, Hricak H (2016) Radiomics: images are more than pictures, they are data. Radiology 278:563–577. https://doi.org/10.1148/radiol.2015151169
Becker AS, Schneider MA, Wurnig MC, Wagner M, Clavien PA, Boss A (2018) Radiomics of liver MRI predict metastases in mice. Eur Radiol Exp 2:11. https://doi.org/10.1186/s41747-018-0044-7
Fradet G, Ayde R, Bottois H et al (2022) Prediction of lipomatous soft tissue malignancy on MRI: comparison between machine learning applied to radiomics and deep learning. Eur Radiol Exp 6:41. https://doi.org/10.1186/s41747-022-00295-9
Jensen LJ, Kim D, Elgeti T, Steffen IG, Hamm B, Nagel SN (2022) Differentiation of pulmonary lymphoma manifestations and nonlymphoma infiltrates in possible invasive fungal disease using fast T1-weighted magnetic resonance imaging at 3 T comparison of texture analysis, mapping, and signal intensity quotients. J Thorac Imaging 37:80–89. https://doi.org/10.1097/RTI.0000000000000606
Jensen LJ, Rogasch JMM, Kim D et al (2022) CT radiomics to predict deauville score 4 positive and negative Hodgkin lymphoma manifestations. Sci Rep 12:20008. https://doi.org/10.1038/s41598-022-24227-0
Aerts HJ, Velazquez ER, Leijenaar RT et al (2014) Decoding tumour phenotype by noninvasive imaging using a quantitative radiomics approach. Nat Commun 5:4006. https://doi.org/10.1038/ncomms5006
Pinto Dos Santos D, Dietzel M, Baessler B (2021) A decade of radiomics research: are images really data or just patterns in the noise? Eur Radiol 31:1–4. https://doi.org/10.1007/s00330-020-07108-w
Wood ML (2020) Variability and standardization of quantitative imaging. Invest Radiol 55:617–618. https://doi.org/10.1097/RLI.0000000000000667
Hagiwara A, Fujita S, Ohno Y, Aoki S (2020) Variability and standardization of quantitative imaging: monoparametric to multiparametric quantification, radiomics, and artificial Intelligence. Invest Radiol 55:601–616. https://doi.org/10.1097/RLI.0000000000000666
Rinaldi L, De Angelis SP, Raimondi S et al (2022) Reproducibility of radiomic features in CT images of NSCLC patients: an integrative analysis on the impact of acquisition and reconstruction parameters. Eur Radiol Exp 6:2. https://doi.org/10.1186/s41747-021-00258-6
Shur J, Blackledge M, D’Arcy J et al (2021) MRI texture feature repeatability and image acquisition factor robustness, a phantom study and in silico study. Eur Radiol Exp 5:2. https://doi.org/10.1186/s41747-020-00199-6
Rizzo S, Botta F, Raimondi S et al (2018) Radiomics: the facts and the challenges of image analysis. Eur Radiol Exp 2:36. https://doi.org/10.1186/s41747-018-0068-z
Berenguer R, Pastor-Juan MDR, Canales-Vazquez J et al (2018) Radiomics of CT features may be nonreproducible and redundant: influence of CT acquisition parameters. Radiology 288:407–415. https://doi.org/10.1148/radiol.2018172361
Jensen LJ, Kim D, Elgeti T, Steffen IG, Hamm B, Nagel SN (2021) Stability of radiomic features across different region of interest sizes-a CT and MR phantom study. Tomography 7:238–252. https://doi.org/10.3390/tomography7020022
Jensen LJ, Kim D, Elgeti T, Steffen IG, Hamm B, Nagel SN (2021) Stability of liver radiomics across different 3D ROI sizes-an MRI in vivo study. Tomography 7:866–876. https://doi.org/10.3390/tomography7040073
Roy S, Whitehead TD, Quirk JD et al (2020) Optimal co-clinical radiomics: sensitivity of radiomic features to tumour volume, image noise and resolution in co-clinical T1-weighted and T2-weighted magnetic resonance imaging. EBioMedicine 59:102963. https://doi.org/10.1016/j.ebiom.2020.102963
Traverso A, Kazmierski M, Zhovannik I et al (2020) Machine learning helps identifying volume-confounding effects in radiomics. Phys Med 71:24–30. https://doi.org/10.1016/j.ejmp.2020.02.010
Choi W, Riyahi S, Kligerman SJ, Liu CJ, Mechalakos JG, Lu W (2018) Technical note: identification of CT texture features robust to tumor size variations for normal lung texture analysis. Int J Med Phys Clin Eng Radiat Oncol 7:330–338. https://doi.org/10.4236/ijmpcero.2018.73027
Jensen LJ, Kim D, Elgeti T et al (2022) Enhancing the stability of CT radiomics across different volume of interest sizes using parametric feature maps: a phantom study. Eur Radiol Exp 6:43. https://doi.org/10.1186/s41747-022-00297-7
Kim D, Jensen LJ, Elgeti T, Steffen IG, Hamm B, Nagel SN (2021) Radiomics for everyone: a new tool simplifies creating parametric maps for the visualization and quantification of radiomics features. Tomography 7:477–487. https://doi.org/10.3390/tomography7030041
Fedorov A, Beichel R, Kalpathy-Cramer J et al (2012) 3D Slicer as an image computing platform for the quantitative imaging network. Magn Reson Imaging 30:1323–1341. https://doi.org/10.1016/j.mri.2012.05.001
Serai SD, Obuchowski NA, Venkatesh SK et al (2017) Repeatability of MR elastography of liver: a meta-analysis. Radiology 285:92–100. https://doi.org/10.1148/radiol.2017161398
PyRadiomics Community (2016) Radiomic features https://pyradiomics.readthedocs.io/en/latest/features.html. Accessed 20 Jan 2023
Zwanenburg A, Vallieres M, Abdalah MA et al (2020) The image biomarker standardization initiative: standardized quantitative radiomics for high-throughput image-based phenotyping. Radiology 295:328–338. https://doi.org/10.1148/radiol.2020191145
R Development Core Team (2016) R: a language and environment for statistical computing. R Foundation for Statistical Computing, Vienna https://www.R-project.org/. Accessed 13 Feb 2023
Lin LI (1989) A concordance correlation coefficient to evaluate reproducibility. Biometrics 45:255–268
Barnhart HX, Haber M, Song J (2002) Overall concordance correlation coefficient for evaluating agreement among multiple observers. Biometrics 58:1020–1027. https://doi.org/10.1111/j.0006-341x.2002.01020.x
Stevenson M, Sergeant E, Heuer C et al (2021) Package “epiR” https://CRAN.R-project.org/package=epiR. Accessed 25 Feb 2023
Santinha J, Bianchini L, Figueiredo M et al (2022) Discrimination of tumor texture based on MRI radiomic features: is there a volume threshold? a phantom study. Appl Sci 12:5465. https://doi.org/10.3390/app12115465
Saltybaeva N, Tanadini-Lang S, Vuong D et al (2022) Robustness of radiomic features in magnetic resonance imaging for patients with glioblastoma: multi-center study. Phys Imaging Radiat Oncol 22:131–136. https://doi.org/10.1016/j.phro.2022.05.006
Fave X, Zhang L, Yang J et al (2016) Impact of image preprocessing on the volume dependence and prognostic potential of radiomics features in non-small cell lung cancer. Transl Cancer Res 5:349–363
Shafiq-Ul-Hassan M, Latifi K, Zhang G, Ullah G, Gillies R, Moros E (2018) Voxel size and gray level normalization of CT radiomic features in lung cancer. Sci Rep 8:10545. https://doi.org/10.1038/s41598-018-28895-9
Shafiq-ul-Hassan M, Zhang GG, Latifi K et al (2017) Intrinsic dependencies of CT radiomic features on voxel size and number of gray levels. Med phys 44:1050–1062. https://doi.org/10.1002/mp.12123
Larue R, van Timmeren JE, de Jong EEC et al (2017) Influence of gray level discretization on radiomic feature stability for different CT scanners, tube currents and slice thicknesses: a comprehensive phantom study. Acta Oncol 56:1544–1553. https://doi.org/10.1080/0284186X.2017.1351624
Ligero M, Jordi-Ollero O, Bernatowicz K et al (2021) Minimizing acquisition-related radiomics variability by image resampling and batch effect correction to allow for large-scale data analysis. Eur Radiol 31:1460–1470. https://doi.org/10.1007/s00330-020-07174-0
Öllers M, Bosmans G, van Baardwijk A et al (2008) The integration of PET-CT scans from different hospitals into radiotherapy treatment planning. Radiother Oncol 87:142–146. https://doi.org/10.1016/j.radonc.2007.12.025
Lu L, Ahmed FS, Akin O et al (2021) Uncontrolled confounders may lead to false or overvalued radiomics signature: a proof of concept using survival analysis in a multicenter cohort of kidney cancer. Front Oncol 11:638185. https://doi.org/10.3389/fonc.2021.638185
Zhang H, Li W, Hu F, Sun Y, Hu T, Tong T (2019) MR texture analysis: potential imaging biomarker for predicting the chemotherapeutic response of patients with colorectal liver metastases. Abdom Radiol (NY) 44:65–71. https://doi.org/10.1007/s00261-018-1682-1
Sim JZT, Hui TCH, Chuah TK, Low HM, Tan CH, Shelat VG (2022) Efficacy of texture analysis of pre-operative magnetic resonance imaging in predicting microvascular invasion in hepatocellular carcinoma. World J Clin Oncol 13:918–928. https://doi.org/10.5306/wjco.v13.i11.918
Runge VM, Heverhagen JT (2022) Signal-to-noise ratio in clinical 3 T. the physics of clinical MR taught through images. Springer, Cham; p. 40−41 https://doi.org/10.1007/978-3-030-85413-3
Rai R, Holloway LC, Brink C et al (2020) Multicenter evaluation of MRI-based radiomic features: a phantom study. Med Phys 47:3054–3063. https://doi.org/10.1002/mp.14173
Ammari S, Pitre-Champagnat S, Dercle L et al (2020) Influence of magnetic field strength on magnetic resonance imaging radiomics features in brain imaging, an in vitro and in vivo Study. Front Oncol 10:541663. https://doi.org/10.3389/fonc.2020.541663
Mayerhoefer ME, Szomolanyi P, Jirak D et al (2009) Effects of magnetic resonance image interpolation on the results of texture-based pattern classification: a phantom study. Invest Radiol 44:405–411. https://doi.org/10.1097/RLI.0b013e3181a50a66
We acknowledge support from the German Research Foundation (DFG) and the Open Access Publication Fund of Charité–Universitätsmedizin Berlin.
Open Access funding enabled and organized by Projekt DEAL. This research received no external funding.
One of the coauthors, BH, receives grants for the Department of Radiology from Abbott, AbbVie, Ablative Solutions, Accovion, Achogen Inc., Actelion Pharmaceuticals, ADIR, Aesculap, Agios Pharmaceuticals, INC., AGO, AIF: Arbeitsgemeinschaft industrieller Forschungsvereinigungen, AIO: Arbeitsgemeinschaft internistische Onkologie, Aktionsbündnis Partnersicherheit e.V., Alexion Pharmaceuticals, Amgen, AO Foundation, Aravive, Arena Pharmaceuticals, ARMO Biosciences, Inc., Array Biopharma Inc., Art photonics GmbH Berlin, ASAS, Ascelia Pharma AB, Ascendis, ASR Advanced sleep research, Astrellas, AstraZeneca, August Research OOF, Sofia, BG, BARD, Basiliea, Bayer Healthcare, Bayer Schering Pharma, Bayer Vital, BBraun, BerGenBioASA, Berlin-Brandenburger Centrum für regenerative Therapie (BCRT), Berliner Krebsgesellschaft, Biontech Mainz, BioNTech SE, Biotronik, Bioven, BMBF, BMS, Boehring Ingelheimer, Boston Biomedical Inc., Boston Scientific Medizintechnik GmbH, BRACCO Group, Brahms GmbH, Brainsgate, Bistol-Myers Squibb, Calithera Biosciences UK, Cantargia AB, Medicon Village, Cascadian Therapeutics, Inc., Celgene, CELLACT Pharma, Celldex Therapeutics, Cellestia Biotech AG CH, CeloNova BioSciences, Charité research organization GmbH, Chiltern, CLOVIS ONCOLOGY, INC., Covance, CRO Charité, CTI Ulm, CUBIST, CureVac AG, Tübingen, Curis, Daiichi Sankyo, Dartmouth College, Hanover, NH, USA, DC Devices, Inc. USA, Delcath Systems, Dermira Inc., Deutsche Krebshilfe, Deutsche Rheuma Liga, DZ–Deutsche Diabetes Forschungsgesellschaft e.V., Deutsches Zentrum für Luft- und Raumfahrt e.V., DFG, Dr. Falk Pharma GmbH, DSM Nutritional Products AG, Dt. Gesellschaft für muskuloskelettale Radiologie, Dt. Stiftung für Herzforschung, Dynavax, Aisai Ltd., European Knowledge Centre, Mosquito Way, Hatfield, Eli Lilly and Company Ltd., EORTC, Episurf Medical, Epizyme, Inc., Essex Pharma, EU Programmes, European society of gastrointestinal and abdominal radiology, Euroscreen S.A., F20 Biotech GmbH, Ferring Pharmaceuticals A/S, Fibrex Medical Inc., Focused Ultrasound Surgery Foundation, Fraunhofer Gesellschaft, GALA Therapeutics, US, Galena Biopharma, Galmed Research and Development Ltd., Ganymed, GBG Forschungs GmbH, GE, Gentech. Inc., Genmab A/S, Genzyme Europe B.V., GETNE (Grupo Espanol de Tumores Neuroendocrinos), Gilead Sciences, Inc., Glaxo Smith Kline, Glycotype GmbH Berlin, Goethe Uni Frankfurt, Guerbet, Guidant Europe NV, Halozyme, Hans-Böckler-Stiftung, Hewlett Packard GmbH, Holaira Inc., Horizon Therapeutics Ireland, ICON (CRO), Idera Pharmaceuticals, Inc., Ignyta, Inc., Immunomedics Inc., Immunocore, Inari Medical Europe GmbH Basel, Incyte, INC Research, Innate Pharma, InSightec Ltd., Inspiremd, InVentiv Health Clinical UK Ltd., Inventivhealth, IO Biotech ApS Copenhagen, IOMEDICO, IONIS, IPSEN Pharma, IQVIA ISA Therapeutics, Isis Pharmaceuticals Inc., ITM Solucin GmbH, Jansen-Cilag GmbH, Kantar Health GmbH (CRO), Kartos Therapeutics, Inc., Karyopharm Therapeutics, Inc., Kendle/MorphoSys AG, Kite Pharma, Kli Fo Berlin Mitte, Kura Oncology, Labcorb, La Roche, Land Berlin, Lilly GmbH, Lion Biotechnology, Lombard Medical, Loxo Oncology, Inc., LSK BioPartners, USA, Lundbeck GmbH, LUX Biosciences, LYSARC, MacroGenics, MagForce, MedImmune Inc., MedImmune Limited, Medpace, Medpace Germany GmbH (CRO), MedPass (CRO), Medtronic, Medtraveo GmbH, Merck, Merrimack Pharmaceuticals Inc., MeVis Medical Solutions AG, Millenium Pharmaceuticals Inc., Miltenyi Biomedicine GmbH, Bergisch Gladbach, miRagen Boukider, Mologen, Monika Kutzner Stiftung, MophoSys AG, MSD Sharp, Nektar Therapeutics, NeoVacs SA, Netzwerkverbund Radiologie, Neurocrine Biosciences Inc., US, Newlink Genetics Corporation, Nexus Oncology, NIH, NOGGO Berlin, Nord-Ostddeutsche Gesellschaft e.V., Novartis, Novocure, Nuvisan, Ockham oncology, Odonate Therapeutics San Diego, OHIRC Kanada, Oppilan Pharma ldt., London, Orion Corporation Orion Pharma, OSE Immunotherapeutics, Parexel CRO Service, Pentixal Pharma GmbH Perceptive, Pfizer GmbH, PharmaCept GmbH, Pharma Mar, Pharmaceutical Reseach Associates GmbH (PRA), Pharmacyclics Inc., Philipps, Philogen s.p.a. Siena, Pliant therapeutics San Francisco, PIQUR Therapeutics Ltd., Pluristem, PneuRX.Inc., Portola Pharmaceuticals, PPD (CRO), PRaint, Precision GmbH, Premier-research, Priovant Therapeutics USA, Provectus Biopharmaceuticals, Inc., psi-cro, Pulmonx International Sarl, Quintiles GmbH, Radiobotics ApS, Regeneraon Pharmaceuticals Inc., Replimune, Respicardia, Rhythm Pharmaceuticals, Inc. Boston USA, Roche, Salix Pharmaceuticals Inc., Samsung, Sanofi, sanofis-aventis S.A., Sarepta Therapeutics, Cambridge, US, Saving Patient’s Lives Medical B.V., Schumacher GmbH, Seagen, Seattle Genetics, Servier (CRO), SGS Life Science Sercives (CRO), Shape Memorial Midical Inc., USA, Shire Human Genetic Therapies, Siemens, Silena Therapeutics, SIRTEX Medical Europe GmbH, SOTIO Biotech, Boston, Spectranetics GmbH, Spectrum Pharmaceuticals, Stiftung Charite/BIH, St. Jude Medical, Stiftung Wolfgang Schulze, Syneos Health UK, Ltd., Symphogen, Taiho Oncology, Inc., Taiho Pharmaceutical Co., Target Pharma Solutions Inc., TauRx Therapeutics Ltd., Terumo Medical Corporation, Tesaro, tetec-ag, TEVA, Theorem, Theradex, Theravance, Threshold Pharmaceuticals Inc., TNS Healthcare GmbH, Toshiba, UCB Pharma, Ulrich GmbH Ulm, Uni Jena, Uni München, Uni Tübingen, Vaccibody A.S., VDI/VDE, Vertex Pharmaceuticals Incorporated, Viridian Therapeutics, US, Virtualscopis LLC, Winicker-norimed, Wyeth Pharma, Xcovery Holding Company, Zukunftsfond Berlin (TSB) outside the submitted work.
Ethics approval and consent to participate
The study was conducted according to the guidelines of the Declaration of Helsinki, and approved by the Institutional Review Board (or Ethics Committee) of Charité Berlin (protocol code [EA1/104/19] and date of approval [May 14 2019]). Patient consent was waived because of retrospective data analysis.
Consent for publication
The authors declare that they have no competing interests.
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Script of the parametric maps.
PyRadiomics settings for the conventional extraction.
IBSI reporting guidelines.
OCCC data for the VOI sizes of 10, 20, and 30 mm from the original images (conventional extraction).
Overview of grayscale behavior of the original images.
OCCC data for the VOI sizes of 20 and 30 mm from the original images (conventional extraction).
Barplots of the OCCCs per scanner (VOI sizes of 10, 20, and 30 mm).
OCCC data for the VOI sizes of 10, 20, and 30 mm from the maps (map extraction).
OCCC data for the VOI sizes of 20 and 30 mm from the maps (map extraction).
Overview of grayscale behavior of the feature maps.
Barplots of the OCCCs per scanner (VOI sizes of 20 and 30 mm).
Overview of the reproducible features.
About this article
Cite this article
Jensen, L.J., Kim, D., Elgeti, T. et al. The role of parametric feature maps to correct different volume of interest sizes: an in vivo liver MRI study. Eur Radiol Exp 7, 48 (2023). https://doi.org/10.1186/s41747-023-00362-9